Evidence map›Paper›PMID 36800138›Full record

ArticleClinical rheumatology2023

Imrecoxib and celecoxib affect sacroiliac joint inflammation in axSpA by regulating bone metabolism and angiogenesis.

Yanke Guo, Dongbin Jiang, Zhiyan Mai, Yufeng Chen, Ting Li, Guanmin Gao

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical rheumatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Imrecoxib: Advances in Pharmacology and Therapeutics.Drug design, development and therapy · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Yanke GuoDepartment of General Practice, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.
Dongbin JiangDepartment of Rheumatology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.
Zhiyan MaiDepartment of Rheumatology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.
Yufeng ChenDepartment of Rheumatology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.
Ting LiDepartment of Rheumatology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.
Guanmin GaoDepartment of Rheumatology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China. guanmingao@zzu.edu.cn.ORCID http://orcid.org/0000-0001-7458-8378
First Affiliated Hospital of Zhengzhou University · CNFifth Affiliated Hospital of Zhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo analyze the changes in the levels of bone metabolism markers related to sacroiliac joint (SIJ) inflammation in patients with axial spondyloarthritis (axSpA) after treatment with imrecoxib and celecoxib and evaluate their relationship with clinical efficacy.

methodsA total of 120 patients with axSpA with at least 2 magnetic resonance imaging (MRI) SIJ scans during a 12-week follow-up were enrolled. The levels of bone metabolism markers, including dickkopf-1(DKK-1), sclerostin, vascular endothelial growth factor (VEGF), bone morphogenetic protein-2 (BMP-2), osteoprotegerin (OPG), noggin, β-catenin, and RUNX2, were measured twice, and their association with disease activity and the Spondyloarthritis Research Consortium of Canada (SPARCC) score for SIJ were analyzed by univariate analysis of covariance.

resultsA total of 116 patients completed the follow-up. The levels of sclerostin, OPG, noggin, DKK-1, and RUNX2 were increased, whereas those of VEGF and β-catenin were decreased. The levels of sclerostin and OPG were negatively correlated with disease duration. The levels of VEGF and β-catenin were significantly decreased (F = 7.866, P = 0.003; F = 4.106, P = 0.047) in patients with disease remission. A decrease in ESR was significantly correlated with decreased levels of Runx2 and SPARCC scores, with the levels of sclerostin being significantly elevated in the SPARCC-reduced group. There were no statistically significant differences between the imrecoxib and celecoxib groups (P> 0.05).

conclusionImrecoxib and celecoxib affect SIJ inflammation, disease activity, and the course of disease by regulating bone metabolism and angiogenesis in axSpA. Key Points •After treatment with imrecoxib and celecoxib, the levels of sclerostin, OPG, noggin, DKK-1, and RUNX2 were increased, whereas those of VEGF and β-catenin were decreased, correlating with the course of disease, disease activity, and SIJ inflammation. • A decrease in ESR was significantly correlated with a decrease in the levels of RUNX2 and SIJ inflammation.. • The levels of sclerostin were more significantly elevated in SIJ inflammation remission group.. •Imrecoxib and celecoxib affect SIJ inflammation by regulating bone metabolism and angiogenesis in axSpA..

Indexed as

Axial SpondyloarthritisSacroiliitisSpondylarthritisbeta CateninCelecoxibCore Binding Factor Alpha 1 SubunitHumansInflammationMagnetic Resonance ImagingPyrrolesSacroiliac JointSulfidesVascular Endothelial Growth Factor Abeta CateninCelecoxibCore Binding Factor Alpha 1 SubunitImrecoxibPyrrolesSulfidesVascular Endothelial Growth Factor AAxial spondyloarthritisBone metabolism markersCelecoxibImrecoxibSacroiliac joint inflammation

Identifiers

PMID36800138
OpenAlexW4321163198

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.